【摘要】 移植后糖尿病(PTDM)是实体器官移植术后最为常见的严重并发症之一,可导致移植术后移植物失功、感染、心血管疾病发生以及急性排斥反应发生,严重影响移植受者生存率与生存质量。随着器官移植的发展,PTDM越来越受到重视。他克莫司作为一种强效免疫抑制剂,目前广泛应用于移植受者,但较易引起PTDM,限制了其在临床的应用。本文就他克莫司致PTDM发病机制研究及治疗进展作一综述。更多还原

【Abstract】 Post-transplantation diabetes mellitus( PTDM) is one of the most common and severe complications after solid organ transplantation. PTDM is a high risk factor for graft dysfunction,infection,cardiovascular complications and acute graft rejection,which affected survival rate and the quality of life of recipients. Tacrolimus is a powerful kind of immunosuppressant which is widely used on organ recipients. However,tacrolimus is more diabetogenic than other kind of immunosuppressant.Here we summarized the research and treatment progress of tacrolimus on PTDM.更多还原